Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.52 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7222716 | 0.82 | MRGPRX1 (0.54) | MRGPRX1 | |
| SCHEMBL7220116 | 0.82 | BCL2L1 (0.48) | BCL2L1MCL1 | |
| SCHEMBL8307237 | 0.80 | AR (0.56) | MRGPRX1BCL2L1MCL1 | |
| SCHEMBL7220823 | 0.78 | ALDH1A1 (0.51) | BCL2L1MCL1 | |
| SCHEMBL7219583 | 0.77 | AR (0.51) | MRGPRX1BCL2L1MCL1 | |
| SCHEMBL7226423 | 0.75 | MRGPRX1 (0.45) | MRGPRX1BCL2L1MCL1 | |
| SCHEMBL27928487 | 0.74 | POLB (0.64) | BCL2L1MCL1 | |
| SCHEMBL13743071 | 0.74 | — | — | |
| SCHEMBL7228467 | 0.73 | KDM4E (0.54) | MRGPRX1 | |
| SCHEMBL12201318 | 0.73 | ACLY (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6573278-B2 | For therapy and prophylaxis of cerebral apoplexy and craniocerebral trauma | BAYER AKTIENGESELLSCHAFT (DE) | 2003-06-03 | — | — | US | disclosed |
| US-20020072529-A1 | Arylsulfonamides and analogues | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2002-06-13 | — | — | US | disclosed |
| US-6262112-B1 | 1-(4,4,4-TRIFLUOROBUTYLSULPHONYLOXY)-3-(2-(HYDROXYMETHYL)INDAN -4-YLOXY)-BENZENE | BAYER AKTIENGESELLSCHAFT (DE) | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072529-A1 | Arylsulfonamides and analogues | ARSA, PRSS12, SNCA | MRGPRX1 1609/4885BCL2L1 646/4885MCL1 2520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.